Browse > Article
http://dx.doi.org/10.3857/roj.2014.32.3.208

Significant fibrosis after radiation therapy in a patient with Marfan syndrome  

Suarez, Eva M. (Department of Radiation Oncology, Medical University of South Carolina)
Knackstedt, Rebecca J. (Department of Radiation Oncology, Medical University of South Carolina)
Jenrette, Joseph M. (Department of Radiation Oncology, Medical University of South Carolina)
Publication Information
Radiation Oncology Journal / v.32, no.3, 2014 , pp. 208-212 More about this Journal
Abstract
Marfan syndrome is one of the collagen vascular diseases that theoretically predisposes patients to excessive radiation-induced fibrosis yet there is minimal published literature regarding this clinical scenario. We present a patient with a history of Marfan syndrome requiring radiation for a diagnosis of a right brachial plexus malignant nerve sheath tumor. It has been suggested that plasma transforming growth factor beta 1 (TGF-${\beta}1$) can be monitored as a predictor of subsequent fibrosis in this population of high risk patients. We therefore monitored the patient's TGF-${\beta}1$ level during and after treatment. Despite maintaining stable levels of plasma TGF-${\beta}1$, our patient still developed extensive fibrosis resulting in impaired range of motion. Our case reports presents a review of the literature of patients with Marfan syndrome requiring radiation therapy and the limitations of serum markers on predicting long-term toxicity.
Keywords
Marfan syndrome; Radiation therapy; Transforming growth factor beta1; Fibrosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Cook JR, Nistala H, Ramirez F. Drug-based therapies for vascular disease in Marfan syndrome: from mouse models to human patients. Mt Sinai J Med 2010;77:366-73.   DOI   ScienceOn
2 Robinson PN, Booms P, Katzke S, et al. Mutations of FBN1 and genotype-phenotype correlations in Marfan syndrome and related fibrillinopathies. Hum Mutat 2002;20:153-61.   DOI   ScienceOn
3 Isogai Z, Ono RN, Ushiro S, et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 2003;278:2750-7.   DOI   ScienceOn
4 Li C, Wilson PB, Levine E, Barber J, Stewart AL, Kumar S. TGFbeta1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis. Int J Cancer 1999;84:155-9.   DOI   ScienceOn
5 Martin M, Lefaix J, Delanian S. TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys 2000;47:277-90.   DOI   ScienceOn
6 Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003;33:407-11.   DOI   ScienceOn
7 Hill RP, Rodemann HP, Hendry JH, Roberts SA, Anscher MS. Normal tissue radiobiology: from the laboratory to the clinic. Int J Radiat Oncol Biol Phys 2001;49:353-65.   DOI   ScienceOn
8 Lafuma C, El Nabout RA, Crechet F, Hovnanian A, Martin M. Expression of 72-kDa gelatinase (MMP-2), collagenase (MMP-1), and tissue metalloproteinase inhibitor (TIMP) in primary pig skin fibroblast cultures derived from radiation-induced skin fibrosis. J Invest Dermatol 1994;102:945-50.   DOI   ScienceOn
9 Anscher MS, Murase T, Prescott DM, et al. Changes in plasma TGF beta levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis. Int J Radiat Oncol Biol Phys 1994;30:671-6.   DOI   ScienceOn
10 Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993;328:1592-8.   DOI   ScienceOn
11 Anscher MS, Kong FM, Andrews K, et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 1998;41:1029-35.   DOI   ScienceOn
12 Pereira L, Andrikopoulos K, Tian J, et al. Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat Genet 1997;17:218-22.   DOI   ScienceOn
13 Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA. Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest 1994;93:892-9.   DOI   ScienceOn
14 Anscher MS, Marks LB, Shafman TD, et al. Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys 2003;56:988-95.   DOI   ScienceOn
15 Matt P, Schoenhoff F, Habashi J, et al. Circulating transforming growth factor-beta in Marfan syndrome. Circulation 2009;120:526-32.   DOI   ScienceOn
16 Nguyen NP, Antoine JE, Dutta S, Karlsson U, Sallah S. Current concepts in radiation enteritis and implications for future clinical trials. Cancer 2002;95:1151-63.   DOI   ScienceOn
17 Phan C, Mindrum M, Silverman C, Paris K, Spanos W. Matched-control retrospective study of the acute and late complications in patients with collagen vascular diseases treated with radiation therapy. Cancer J 2003;9:461-6.   DOI
18 Winchester DP, Cox JD. Standards for diagnosis and management of invasive breast carcinoma. CA Cancer J Clin 1998;48:83-107.   DOI   ScienceOn
19 Anscher MS, Thrasher B, Zgonjanin L, et al. Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury. Int J Radiat Oncol Biol Phys 2008;71:829-37.   DOI   ScienceOn
20 Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008;358:2787-95.   DOI   ScienceOn